NCT03619616 - Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Ascending Dose of ZSP1603 in Healthy Adults | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 16, 2018

Primary Completion Date

June 28, 2019

Study Completion Date

October 22, 2019

Conditions

Idiopathic Pulmonary Fibrosis(IPF)Solid Tumor

Interventions

DRUG

ZSP1603 7.5 mg

ZSP1603 capsule administered orally once daily under fasted condition.

DRUG

ZSP1603 12.5 mg

ZSP1603 capsule administered orally once daily in the fasting state.

DRUG

Placebo 12.5mg

Participants will receive placebo matching to ZSP1603 orally once daily under fasted condition.

DRUG

ZSP1603 25 mg

ZSP1603 capsule administered orally once daily under fasted condition.

DRUG

Placebo 25mg

Participants will receive placebo matching to ZSP1603 orally once daily in the fasting state.

DRUG

ZSP1603 50 mg

ZSP1603 capsule administered orally once daily under fasted state.

DRUG

Placebo 50mg

Participants will receive placebo matching to ZSP1603 orally once daily in the fasting state.

Trial Locations (1)

The Third Xiangya Hospital of Central South University, Changsha

All Listed Sponsors

lead

Guangdong Zhongsheng Pharmaceutical Co., Ltd.

INDUSTRY